Document is current
Any future updates will be listed below
-
Authors
Oswald, Laura B. https://orcid.org/0000-0001-6281-2512
Li, Xiaoyin
Gudenkauf, Lisa M. https://orcid.org/0000-0001-6825-5921
De Avila, Gabe
Scheiber-Camoretti, David
Small, Brent J. https://orcid.org/0000-0002-7444-4689
Gonzalez, Brian D. https://orcid.org/0000-0001-5108-5735
Hoogland, Aasha I. https://orcid.org/0000-0002-8691-8132
Nguyen, Oanh
Rodriguez, Yvelise
Crowder, Sylvia L.
Parker, Nathan H.
Carson, Tiffany L.
Vinci, Christine E.
Baz, Rachid C.
Shain, Kenneth H. https://orcid.org/0000-0003-4178-8888
Blue, Brandon
Grajales-Cruz, Ariel
Matte, Kristy
Kale, Brandon
Kaldas, David
Perna, Fabiana
Alsina, Melissa
Freeman, Ciara L.
Castaneda Puglianini, Omar https://orcid.org/0000-0003-0423-5870
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Liu, Hien
Locke, Frederick L. https://orcid.org/0000-0001-9063-6691
Jim, Heather S. L. https://orcid.org/0000-0001-7353-3711
Peres, Lauren C.
Hansen, Doris K. https://orcid.org/0000-0002-9813-3578
- License Information
-
More Information
Article History
Received: 7 November 2025
Revised: 25 March 2026
Accepted: 20 April 2026
First Online: 11 May 2026
Competing interests
: This study was conducted with support from the Participant Research, Interventions, and Measurement (PRISM) Core and funded in part by a Pentecost Family Myeloma Research Center award (MPIs: DKH, LBO, LCP) at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center (P30CA076292). The authors have the following competing interests to disclose: LBO: Research funding: the National Institutes of Health and the Department of Defense. BDG: Consulting: Janssen; Advisory board/honoraria: Elly Health; Patents, royalties, or other intellectual property: licensing fees received by Moffitt Cancer Center. RCB: Advisory board: Janssen, Bristol-Myers Squibb, Pfizer, and GSK; Research funding: Bristol-Myers Squibb, Janssen, Abbvie, Karyopharm, and Regeneron. KHS: Honoraria: Abbvie, Adaptive, Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Kite/Arcellx, Regeneron, Sanofi, and Takeda; Research funding to the institution outside the submitted work: AbbVie, Pfizer, and Karyopharm. BB: Consulting: Pfizer Pharmaceutics, Janssen Pharmaceutics, Oncopeptides, Kite Pharmaceuticals, and Sanofi Pharmaceutics; Honoraria: Abbvie. AGC: Advisory board: Cellectar, Janssen, and Sanofi; Speaker bureau: Amgen and Sanovi. FP: Research funding: the National Institutes of Health. MA: Advisory board: Janssen, Bristol-Myers Squibb, and Sanofi; Research funding: Janssen, Bristol-Myers Squibb, Pfizer, and Sanofi. CLF: Honoraria/consulting: Bristol-Myers Squibb, Seattle Genetics, Cellgene, AbbVie, Sanofi, Incyte, Amgen, ONK therapeutics, and Janssen; Research funding: Bristol-Myers Squibb, Janssen, and Roche/Genentech. OCP: Honoraria/Consulting: Legend Biotech Inc, Bristol Myers Squibb, and Janssen Biotech Inc. TN: Clinical trial support: Novartis and Karyopharm. FLL: Advisory/consulting: A2, Allogene, Amgen, Bluebird Bio, Bristol-Myers Squibb/Celgene, Calibr, Caribou, Cellular Biomedicine Group, Cowen, Daiichi Sankyo, EcoR1, Emerging Therapy Solutions, GammaDelta Therapeutics, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja, and Phizer; Contracts for service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), Bristol-Myers Squibb (Institutional), National Cancer Institute, and the Leukemia and Lymphoma Society; Patents, royalties, other intellectual property: several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or editorial activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, and the Society for Immunotherapy of Cancer. HSLJ: Consulting: SBR Biosciences; Research funding: Kite Pharma. LCP: Research funding: Bristol-Myers Squibb, Karyopharm, Janssen, the National Institutes of Health, and the Department of Defense; Support for attending Tandem ASTCT/CIMBTR Annual Meeting (2023). DKH: Consulting or advisory role: Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm; Research funding: Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech. The other authors have no competing interests to disclose.
